NCT00070473已完成1 期
A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 37
- 主要终点
- Event Free Survival
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, use different ways to stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed disodium in treating young patients with recurrent solid tumors.
详细描述
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of pemetrexed disodium in children and adolescents with refractory solid tumors.
- Determine the dose-limiting toxic effects of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
Secondary
- Determine, preliminarily, the antitumor activity of this drug in these patients.
- Correlate the presence of the C677T polymorphism of the methylenetetrahydrolate reductase gene, the presence of a polymorphism in the enhancer region of the thymidylate synthase (TS) gene promoter (2R and 3R tandem repeats), the presence of a polymorphism within one of those repeats, and the presence of a functional polymorphism in the 3'-untranslated region with toxicity in patients treated with this drug.
- Correlate homocysteine and methylmalonic acid levels at study entry with toxicity in patients treated with this drug.
- Correlate various gene expression profiles with response in patients treated with this drug.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Event Free Survival
时间窗: Length of study
次要结局
- Dose Limiting Toxicity(Length of study)
- Maximum Tolerated Dose(Length of study)
研究者
研究点 (37)
Loading locations...
相似试验
已完成
2 期
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00087087Gynecologic Oncology Group51
已完成
2 期
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the CervixCervical CancerNCT00087113Gynecologic Oncology Group
终止
2 期
Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar PregnancyGestational Trophoblastic TumorNCT00096187Gynecologic Oncology Group55
已完成
2 期
Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial CancerEndometrial CancerNCT00087100Gynecologic Oncology Group51
已完成
2 期
Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerLung CancerNCT00268489Alliance for Clinical Trials in Oncology48